Inclisiran in Patients Post-Myocardial Infarction: ORION-10 and ORION-11 Analysis

A heart attack often occurs when blood vessels supplying the heart with oxygen are blocked by a clot. The "bad" cholesterol, LDL cholesterol, plays a key role. It builds up in vessel walls, forming plaques that constrict blood flow. If a plaque ruptures, it can cause a clot that fully blocks the artery, leading to a heart attack. To mitigate this risk, lowering LDL cholesterol with medication is essential. Inclisiran, an innovative siRNA-based drug, effectively targets high LDL cholesterol levels by inhibiting a protein responsible for its increase, thereby reducing LDL cholesterol. Extensive studies (ORION-10,11) have shown that inclisiran reduces LDL cholesterol by approximately 50% in both post-heart attack patients and those without prior heart attacks. A major advantage of inclisiran is its twice-yearly administration, improving adherence by eliminating the need for daily tablets. This convenience can be transformative, especially for patients who struggle to manage their cholesterol levels effectively.